Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a leading biopharmaceutical company dedicated to advancing the discovery and development of innovative medicines focused on cellular metabolism. The company specializes in pioneering therapies that target critical metabolic pathways to address unmet medical needs.

Agios Pharmaceuticals is at the forefront of developing PYRUKYND (mitapivat), a potent activator of both wild-type and mutant pyruvate kinase (PK) enzymes. This breakthrough treatment shows promise in effectively managing hemolytic anemias, demonstrating the company's commitment to transforming patient outcomes through metabolic science.

In addition to PYRUKYND, Agios Pharmaceuticals is advancing AG-946, another PK activator tailored for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias. These innovative therapies underscore the company's dedication to leveraging metabolic insights to address complex diseases.

Founded in 2007, Agios Pharmaceuticals has rapidly established itself as a leader in the biopharmaceutical industry. With a robust pipeline and a focus on cutting-edge research, the company continues to drive forward its mission to develop transformative treatments that improve the lives of patients worldwide.